# A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

> **NCT03859869** · PHASE4 · TERMINATED · sponsor: **AbbVie** · enrollment: 1 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency (EPI)

## Interventions

- **DRUG:** Pancrelipase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03859869
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-25
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-03-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business Considerations (difficulty with enrollment)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03859869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03859869, "A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03859869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*